Archive | Multaq RSS feed for this section
FDA warning on Multaq and Increased Risk of Death
U.S. Food and Drug Administration has completed a safety review of Multaq (generic name dronedarone). According to this review, in patients with permanent atrial fibrillation (AF), Multaq increased the risk of serious cardiovascular events, including death. The data was obtained from ATHENA and PALLAS clinical trials. New information and recommendations are being provided by FDA for [...]
Continue reading...
- Risperdal (Resperidone)
- FDA issues warning on Advair, Symbicort, Foradil and Serevent
- Crestor Linked to Rhabdomyolysis (Fatal Muscle Disease)
- Benzoyl Peroxide Acne Cream 10% Contained Burkholderia Cepacia Bacteria
- Merck’s Vioxx $4.85 billion payouts to begin in August
- Zoloft lawsuit
- Fluoroquinolone Antimicrobial Drugs
- Arthritis Drug Vioxx Recalled
- Tysabri monotherapy and progressive multifocal leukoencephalopathy
- FDA recalls Zyprexa
- None found
- Pfizer birth control pills may not prevent pregnancy
- Adcetris brain infection death
- FDA warning on Multaq and Increased Risk of Death
- SSRI and Potential Risk of Persistent Pulmonary Hypertension
- Serious Complications Associated with Vaginal Mesh devices
- Actos Lawsuit
- Infant heart defect risks increase with SSRIs
- Birth defects more likely with SSRI use
- Diflucan during pregnancy poses risk to infants
- Birth defects caused by many factors
Actos
Arthritis
Avandia
birth defect
birth defects
bladder cancer
Blood pressure
cardiovascular
Class Action
Crestor
Darvon
Deaths
diabetes
esophageal cancer
Genentech
GlaxoSmithKline
heart
heart attacks
heart problems
Heparin
Lawsuit
lawsuits
Levaquin
liver damage
Merck
Osteoporosis
paxil
Pfizer
pregnancy
propoxyphene
Recall
Rhabdomyolysis
RISPERDAL
rofecoxib
schizophrenia
Seroquel
Side Effects
SSRI
Statin
Tylenol
Type 2 diabetes
Vioxx
Zoloft
Zoloft lawsuit
Zyprexa
22. December 2011
0 Comments